A Universal Cancer Vaccine?

A vaccine that targets 90 percent of all cancers shows promise in early clinical trials.

By | April 10, 2012

Dreamstime.com, Suto Norbert


A vaccine that targets the vast majority of cancers has produced encouraging preliminary results in phase I/II clinical trials. According to an announcement made on April 2 by the vaccine’s maker, Vaxil Biotherapeutics, the ImMucin vaccine consists of a 21 amino acid-long peptide that represents a key signaling region of Mucin 1, cell surface associated (or MUC1)—a glycoprotein expressed by 90 percent of solid and non-solid tumors.

In trials carried out at Hadassah Medical Centre in Jerusalem, the vaccine generated a robust immune response in patients with multiple myeloma after only 2 to 4 doses of the vaccine, The Telegraph reported. The patients were administered a maximum of 12 doses.

"In some of the patients, preliminary signs of clinical efficacy were observed," according to a statement from Vaxil Biotheraputics, which will formally publish the results of the trial in the near future.

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Genetic Test Solves Royal Mystery
    Notebook Genetic Test Solves Royal Mystery

    Genetic analyses lay to rest conspiracy theories about death of Belgian King Albert I, who lost his life in a rock climbing accident more than 80 years ago.

  2. Investigation Finds Pathologist Guilty of Systemic Misconduct
  3. Bacteria and Humans Have Been Swapping DNA for Millennia
  4. Curious George
    The Scientist Curious George

    George Church has consistently positioned himself at genomics’ leading edge.